Bacteriological and clinical studies on NM441

Yoshio Kobayashi, Hiroshi Uchida, Mitsuru Murata, Yasuo Ikeda

Research output: Contribution to journalArticle

Abstract

The in vitro activity of NM394, an active form of the newly developed quinolone NM441, for oral use, was studied by determining minimum inhibitory concentration (MIC) by an agar two-fold dilution method. The MICs of NM394 ranged from 0.78 to more than 100μg/ml against 16 strains of Staphylococcus aureus with the mecA gene, but showed excellent activity against 10 strains without the mecA gene and against which the MICs of NM394 ranged from 0.2 to 0.78μg/ml. NM394 was more active than ofloxacin (OFLX) and fleroxacin (FLRX) and almost equally active to ciprofloxacin (CPFX) against S. aureus without the mecA gene. NM394 was more active than OFLX, CPFX and FLRX against Escherichia coli and Klebsiella pneumoniae. The MICs of NM394 ranged from 0.025 or less to 0.1μg/ml against E. coli, from 0.025 or less to 3.13μg/ml against K. pneumoniae, and 0.1 to 25μg/ml against Pseudomonas aeruginosa. NM394 was more active than OFLX and FLRX and almost equally active to CPFX against P. aeruginosa. Two patients with acute pharyngitis and acute bronchitis were successfully treated by administration of 400mg b.i.d. a day of NM441, a prodrug of NM394. No significant side effects or abnormalities of laboratory data were detected after administration of NM441.

Original languageEnglish
Pages (from-to)588-590
Number of pages3
JournalJapanese Journal of Chemotherapy
Volume44
Issue numberSUPPL. 1
Publication statusPublished - 1996

Fingerprint

Fleroxacin
Ofloxacin
Ciprofloxacin
Klebsiella pneumoniae
Pseudomonas aeruginosa
Staphylococcus aureus
Escherichia coli
Genes
Pharyngitis
prulifloxacin
Clinical Studies
ulifloxacin
Bronchitis
Quinolones
Prodrugs
Microbial Sensitivity Tests
Agar

Keywords

  • NM394
  • NM441

ASJC Scopus subject areas

  • Pharmacology

Cite this

Kobayashi, Y., Uchida, H., Murata, M., & Ikeda, Y. (1996). Bacteriological and clinical studies on NM441. Japanese Journal of Chemotherapy, 44(SUPPL. 1), 588-590.

Bacteriological and clinical studies on NM441. / Kobayashi, Yoshio; Uchida, Hiroshi; Murata, Mitsuru; Ikeda, Yasuo.

In: Japanese Journal of Chemotherapy, Vol. 44, No. SUPPL. 1, 1996, p. 588-590.

Research output: Contribution to journalArticle

Kobayashi, Y, Uchida, H, Murata, M & Ikeda, Y 1996, 'Bacteriological and clinical studies on NM441', Japanese Journal of Chemotherapy, vol. 44, no. SUPPL. 1, pp. 588-590.
Kobayashi Y, Uchida H, Murata M, Ikeda Y. Bacteriological and clinical studies on NM441. Japanese Journal of Chemotherapy. 1996;44(SUPPL. 1):588-590.
Kobayashi, Yoshio ; Uchida, Hiroshi ; Murata, Mitsuru ; Ikeda, Yasuo. / Bacteriological and clinical studies on NM441. In: Japanese Journal of Chemotherapy. 1996 ; Vol. 44, No. SUPPL. 1. pp. 588-590.
@article{fd7b41ea4d9547dfb244ed6db06156b5,
title = "Bacteriological and clinical studies on NM441",
abstract = "The in vitro activity of NM394, an active form of the newly developed quinolone NM441, for oral use, was studied by determining minimum inhibitory concentration (MIC) by an agar two-fold dilution method. The MICs of NM394 ranged from 0.78 to more than 100μg/ml against 16 strains of Staphylococcus aureus with the mecA gene, but showed excellent activity against 10 strains without the mecA gene and against which the MICs of NM394 ranged from 0.2 to 0.78μg/ml. NM394 was more active than ofloxacin (OFLX) and fleroxacin (FLRX) and almost equally active to ciprofloxacin (CPFX) against S. aureus without the mecA gene. NM394 was more active than OFLX, CPFX and FLRX against Escherichia coli and Klebsiella pneumoniae. The MICs of NM394 ranged from 0.025 or less to 0.1μg/ml against E. coli, from 0.025 or less to 3.13μg/ml against K. pneumoniae, and 0.1 to 25μg/ml against Pseudomonas aeruginosa. NM394 was more active than OFLX and FLRX and almost equally active to CPFX against P. aeruginosa. Two patients with acute pharyngitis and acute bronchitis were successfully treated by administration of 400mg b.i.d. a day of NM441, a prodrug of NM394. No significant side effects or abnormalities of laboratory data were detected after administration of NM441.",
keywords = "NM394, NM441",
author = "Yoshio Kobayashi and Hiroshi Uchida and Mitsuru Murata and Yasuo Ikeda",
year = "1996",
language = "English",
volume = "44",
pages = "588--590",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Bacteriological and clinical studies on NM441

AU - Kobayashi, Yoshio

AU - Uchida, Hiroshi

AU - Murata, Mitsuru

AU - Ikeda, Yasuo

PY - 1996

Y1 - 1996

N2 - The in vitro activity of NM394, an active form of the newly developed quinolone NM441, for oral use, was studied by determining minimum inhibitory concentration (MIC) by an agar two-fold dilution method. The MICs of NM394 ranged from 0.78 to more than 100μg/ml against 16 strains of Staphylococcus aureus with the mecA gene, but showed excellent activity against 10 strains without the mecA gene and against which the MICs of NM394 ranged from 0.2 to 0.78μg/ml. NM394 was more active than ofloxacin (OFLX) and fleroxacin (FLRX) and almost equally active to ciprofloxacin (CPFX) against S. aureus without the mecA gene. NM394 was more active than OFLX, CPFX and FLRX against Escherichia coli and Klebsiella pneumoniae. The MICs of NM394 ranged from 0.025 or less to 0.1μg/ml against E. coli, from 0.025 or less to 3.13μg/ml against K. pneumoniae, and 0.1 to 25μg/ml against Pseudomonas aeruginosa. NM394 was more active than OFLX and FLRX and almost equally active to CPFX against P. aeruginosa. Two patients with acute pharyngitis and acute bronchitis were successfully treated by administration of 400mg b.i.d. a day of NM441, a prodrug of NM394. No significant side effects or abnormalities of laboratory data were detected after administration of NM441.

AB - The in vitro activity of NM394, an active form of the newly developed quinolone NM441, for oral use, was studied by determining minimum inhibitory concentration (MIC) by an agar two-fold dilution method. The MICs of NM394 ranged from 0.78 to more than 100μg/ml against 16 strains of Staphylococcus aureus with the mecA gene, but showed excellent activity against 10 strains without the mecA gene and against which the MICs of NM394 ranged from 0.2 to 0.78μg/ml. NM394 was more active than ofloxacin (OFLX) and fleroxacin (FLRX) and almost equally active to ciprofloxacin (CPFX) against S. aureus without the mecA gene. NM394 was more active than OFLX, CPFX and FLRX against Escherichia coli and Klebsiella pneumoniae. The MICs of NM394 ranged from 0.025 or less to 0.1μg/ml against E. coli, from 0.025 or less to 3.13μg/ml against K. pneumoniae, and 0.1 to 25μg/ml against Pseudomonas aeruginosa. NM394 was more active than OFLX and FLRX and almost equally active to CPFX against P. aeruginosa. Two patients with acute pharyngitis and acute bronchitis were successfully treated by administration of 400mg b.i.d. a day of NM441, a prodrug of NM394. No significant side effects or abnormalities of laboratory data were detected after administration of NM441.

KW - NM394

KW - NM441

UR - http://www.scopus.com/inward/record.url?scp=0029871285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029871285&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 588

EP - 590

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 1

ER -